The frog skin host-defense peptide tigerinin-1R stimulates insulin release in vitro and improves glucose tolerance and insulin sensitivity in animal models of type 2 diabetes. This study extends these observations by investigating the molecular mechanisms of action underlying the beneficial metabolic effects of the analogue [Arg 4 ] tigerinin-1R in mice with diet-induced obesity, glucose intolerance and insulin resistance. The study also investigates the electrophysiological effects of the peptide on K ATP and L-type Ca 2+ channels in BRIN-BD11 clonal β cells. Non-fasting plasma glucose and glucagon concentrations were significantly (p < 0.05) decreased and plasma insulin increased by twice daily treatment with [Arg 4 ]tigerinin-1R (75 nmol/kg body weight) for 28 days. Oral and intraperitoneal glucose tolerance were significantly (p < 0.05) improved accompanied by enhanced secretion and action of insulin. The peptide blocked K ATP channels and, consistent with this, improved beta cell responses of isolated islets to a range of secretagogues. Peptide administration resulted in up-regulation of key functional genes in islets involved insulin secretion (Abcc8, Kcnj11, Cacna1c and Slc2a2) and in skeletal muscle involved with insulin action (Insr, Irs1, Pdk1, Pik3ca, and Slc2a4). These observations encourage further development of tigerinin-1R analogues for the treatment of patients with type 2 diabetes.
Introduction
The increasing incidence of diabetes mellitus together with challenges posed by diabetic complications has stimulated efforts to discover new anti-diabetic agents with better therapeutic outcomes and lack of adverse sideeffects. Particular emphasis has been placed on molecules isolated from natural sources (Chan and Ye, 2013) and the successful clinical application of exendin-4, a peptide first isolated from the venom of the Gila monster lizard, Herloderma suspectum (Eng et al., 1992) , justifies this approach (Syed and McCormack, 2015) . Amphibian skin secretions have proved to be a rich source of peptides with a wide range of pharmacological properties that may have therapeutic relevance (Pukala et al., 2006; Conlon et al., 2014; Xu and Lai, 2015) . Our programme of investigation has focussed upon amphibian skin peptides that show potential for development into anti-diabetic agents. A number of such peptides are able to stimulate insulin secretion from BRIN-BD11 clonal β-cells and isolated mouse pancreatic islets in vitro (Abdel-Wahab et al., 2008; Ojo et al., 2013; Srinivasan et al., 2014; Owolabi et al., 2016) and improve glycaemic control in vivo in various animal models of type 2 diabetes (Ojo et al., 2015a,b; Srinivasan et al., 2015 Srinivasan et al., , 2016 .
Tigerinin-1R (RVCSAIPLPICH.NH 2 ) was first isolated from norepinephrine-stimulated skin secretions of the Asian frog Hoplobatrachus rugulosus (Dicroglossidae) (Ojo et al., 2011) . The peptide lacks both antimicrobial and haemolytic activities at concentrations up 500 μm but stimulates production of the anti-inflammatory cytokine IL-10 in mouse peritoneal macrophages and human peripheral blood mononuclear cells (Pantic et al., 2014) . Previous studies with tigerinin-1R and its analogues revealed potent insulinotropic actions in vitro (Ojo et al., 2011; Srinivasan et al., 2014) and beneficial effects on glycaemic control in vivo in mice with diet induced obesity and insulin resistance (Ojo et al., 2015a) . Studies with the analogue [Trp 10 ]tigerinin-1R in this model showed that, in addition to its beneficial actions in enhancing insulin sensitivity and beta cell secretory function, the peptide reduced adiposity and plasma triglycerides . However, the exact molecular mechanisms that mediate such actions are not well understood.
The present study extends our investigations of the anti-diabetic effects of tigerinin-1R peptides by studying the mechanisms of action of a more cationic analogue in which the Ser 4 residue is replaced by Arg. Based on previous investigations with peptides such as pseudin-2 (Abdel- Wahab et al., 2008) and alyteserin-2a (Ojo et al., 2013 ) such a modification may be expected to lead to increased insulinotropic activity. In fact, a previous structure-activity study has demonstrated that [Arg 4 ]tigerinin-1R is more effective than the native peptide in stimulating the release of insulin from BRIN-BD11 cells and isolated mouse pancreatic islets (Srinivasan et al., 2014) . The present study investigates metabolic effects, structural and functional changes in the islets of Langerhans, and alterations in the expression of key genes involved in β-cell function and insulin action of long-term (28 days) administration of [Arg 4 ]tigerinin-1R in mice fed a high-fat diet to produce obesity, glucose intolerance, and insulin resistance (Winzell and Ahren, 2004) . In addition, the direct actions of the peptide on ion channels in mouse BRIN-BD11 clonal β-cells were investigated using whole-cell patch-clamp techniques.
Results

Effects of [Arg 4 ]tigerinin-1R on body weight, food intake and non-fasting plasma glucose and insulin concentrations
High-fat fed mice had increased body weight, food intake, plasma glucose and insulin concentrations compared with control mice fed a normal rodent diet (Figure 1 ). ]tigerinin-1R-treatment for 28 days did not affect body weight or energy intake but produced a 32% (p < 0.05, Figure 1C ) reduction in non-fasting plasma glucose accompanied by a 39% (p < 0.05, Figure 1D ) increase in non-fasting plasma insulin compared with saline-treated controls.
Effects of [Arg 4 ]tigerinin-1R on glucose tolerance and insulin sensitivity
Impaired glycaemic responses to intraperitoneal and oral administration were observed in saline-treated high-fat fed mice (Figure 2) . However, treatment with [Arg 4 ]tigerinin-1R improved glycaemic excursion following intraperitoneal (48%, p < 0.05, Figure 2A , B) and oral (66%, p < 0.05, Figure 2E , F) glucose administration in these animals. Similarly, insulin secretory responses to intraperitoneal (2.1-fold, p < 0.05, Figure 2C , D) and oral glucose (2.4-fold, p < 0.05, Figure 2E , F) were also significantly improved in peptide-treated mice. Moreover, insulin sensitivity in [Arg 4 ]tigerinin-1R-treated mice improved by 47% (p < 0.05) compared with saline-treated controls (Figure 2 I, J).
Effects of [Arg 4 ]tigerinin-1R on body composition
Bone mineral density, bone mineral content and lean body mass were similar in all groups of mice (Supplementary Figure 1B , C, E). Reduced bone area (15%, p < 0.001) caused by high-fat feeding was prevented by treatment with [Arg 4 ]tigerinin-1R (Supplementary Figure 1D) . Moreover, [Arg 4 ]tigerinin-1R-treatment inhibited adipose tissue deposition by 19% (p < 0.01, Supplementary Figure 1F) and body fat as a percentage of total body mass by 9% (p < 0.05, Supplementary Figure 1G ).
Effects of [Arg 4 ]tigerinin-1R on pancreatic weight, and the insulin content and insulin secretory responses of isolated islets
Similar pancreatic weights were observed in all groups of mice ( Figure 3A ) but higher total pancreatic insulin content (1.5-fold, p < 0.01) was observed in high-fat fed mice. This elevation of pancreatic insulin content was reduced in mice treated with [Arg 4 ]tigerinin-1R ( Figure 3B ). In addition, the impaired secretory responses of islets isolated from high-fat fed mice to 1.4 mm (p < 0.05), 5.6 mm (p < 0.01) or 16.7 mm glucose (p < 0.01), 1 μm GLP-1 (p < 0.001), 1 μm GIP (p < 0.001), 10 mm alanine (p < 0.001), 10 mm arginine (p < 0.001) and 30 mm KCl (p < 0.01) were restored to the levels observed in lean mice by treatment with [Arg 4 ]tigerinin-1R ( Figure 3C ).
Effects of [Arg 4 ]tigerinin-1R on islet morphology, and β-and α cell area
The islet size, number of islets per mm 2 of pancreas as well as β-and α-cell areas were significantly higher in saline-treated high-fat fed mice compared to lean mice (Supplementary Figure 2) . Treatment with [Arg 4 ]tigerinin-1R for 28 days did not affect these parameters (Supplementary Figure 2B) .
Effects of [Arg 4 ]tigerinin-1R on the expression of genes involved in insulin secretion and insulin action
The names of the genes investigated are summarised in Table 1 . Expression of the insulin 1 Ins1 (2.8-fold, p < 0.01, Figure 4A ), glucose transporter 2 Slc2a2 (1.8-fold, p < 0.05, Figure 4B ), potassium channel 11 Kcnj11 (2.4-fold, p < 0.05, Figure 4D ) and calcium channel Cacna1c (2.2-fold, p < 0.05, Figure 4E ) genes were up-regulated in high-fat fed mice. High-fat feeding did not affect the expression of the ATP-binding cassette transporterAbcc8 gene in islets ( Figure 4C ) or expression of the insulin receptor Insr and insulin receptor substrate 1 Irs1 genes in skeletal muscle ( Figure 4F , G). However, there was down-regulation of the phosphatidylinositol-4,5-bisphosphate kinase Pik3ca (4.4-fold, p < 0.01, Figure 4H ), phosphoinositide-dependent kinase 1 Pdk1 (1.4-fold, p < 0.05, Figure 4I ) and glucose transporter 4 Slc2a4 (1.5-fold, p < 0.05, Figure 5J ) genes in skeletal muscle.
In the islets of mice treated with [Arg 4 ]tigerinin-1R, expression of Ins1 increased 1.2-fold (p < 0.05) compared with saline-treated high-fat fed controls and there were similar significant expression of Slc2a2 (1.5-fold, p < 0.05), Abcc8 (2.2-fold, p < 0.01), Kcnj11 (1.5-fold, p < 0.01) and Cacna1c (1.9-fold, p < 0.01). In skeletal muscle of mice treated with [Arg 4 ]tigerinin-1R, expression of Pdk1 in skeletal muscle was restored to the level observed in lean mice while the expression of Insr (2.9-fold, p < 0.001), Irs1 (3.9-fold, p < 0.01), Pik3ca (6.4-fold, p < 0.01), and Slc2a4 (2.5-fold, p < 0.01) genes was significantly up-regulated compared with saline-treated high-fat fed controls.
Effects of [Arg 4 ]tigerinin-1R on pancreatic and plasma glucagon content and glucagon gene expression
Pancreatic and plasma glucagon levels were elevated by 3.3-fold (p < 0.01, Figure 5A ) and 1.8-fold (p < 0.05, Figure 5B ), respectively in high-fat fed mice compared with lean controls. Elevated expression of the Gcg glucagon gene (1.5-fold, p < 0.05) was also observed in the pancreatic islets of high-fat fed mice ( Figure 5C ). Treatment with [Arg 4 ]tigerinin-1R for 28 days reduced pancreatic glucagon content in high-fat fed mice by 57% and restored plasma glucagon concentrations as well as the expression of the Gcg gene in islets to levels observed in lean mice.
Effects of [Arg 4 ]tigerinin-1R on lipid profile and enzyme markers of renal and liver function
Plasma total cholesterol and LDL cholesterol were similar in all groups of mice while high-fat fed mice exhibited reduced plasma HDL cholesterol (21%, p < 0.05) and elevated plasma triglycerides (1.4-fold, p < 0.05) (Supplementary Figure 3A) . Treatment of mice with [Arg 4 ]tigerinin-1R for 28 days resulted in decreased plasma triglycerides while other parameters were not affected. Plasma concentrations of aspartic acid transaminase (AST) and 
Slc2a4
Glucose transporter 4 (GLUT4) F-ACTAGATCCCGGAGAGCCTTG R-TGGAAACCCGACGGCATCTT 180
Other genes Ins1 ]tigerinin-1R for 28 days had no effect on plasma ALP but resulted in decreased plasma creatinine concentration (40%, p < 0.01, Supplementary Figure 3E ).
Effects of [Arg 4 ]tigerinin-1R on the function of ion channels involved in insulin secretion
Insulin release is dependent on closure of K ATP channels and activation of L-Type Ca 2+ channels. The effects of [Arg 4 ] tigerinin-1R on the activity of these channels was investigated using whole-cell patch-clamp recording in BRIN-BD11 clonal β-cells. Application of the K ATP channel opener diazoxide (200 μm) resulted in an increase in the peak inward current recorded at -80 mV which was reversed by the application of 1 μm 
Discussion
Current approaches for the treatment of type 2 diabetes include the use of agents which stimulate insulin secretion, suppress circulating glucagon concentrations, inhibit starch digestion, delay gastric emptying, improve insulin action, enhance glucose excretion, and mimic the actions of endogenous enzymes involved in the glucose homeostasis (Kahn et al., 2014) . However, there is a constant need for new compounds with superior actions on these or alternative pathways that also lack adverse side-effects. Our recent studies have shown that peptides based on the structure of tigerinin-1R possess properties which encourage their development as agents for the treatment of type 2 diabetes (Ojo et al., 2015a; Srinivasan et al., 2016) but their mechanism of action is not understood. This study has attempted to gain Defective insulin secretion resulting in impaired glucose tolerance is a characteristic feature of high-fat fed mice (Winzell and Ahren, 2004) . Consistent with previous studies with tigerinin-1R (Ojo et al., 2015a) ]tigerinin-1R for 28 days reversed the defect in insulin secretion and improved glycaemic responses to both oral and intraperitoneal glucose. Gene expression analysis has shown that this effect is mediated, at least in part, by upregulation of the Ins1 gene with resulting elevated pancreatic insulin content. Increased expression of the insulin gene is a general feature the hyperglycaemic state (Andrali et al., 2008) . In addition, expression of the Kcnj11 (potassium inwardly rectifying channel), Abcc8 (ATP-binding cassette), Cacna1c (voltage-dependent calcium channel) and Slc2a2 (GLUT2 glucose transporter) genes were all upregulated in islets isolated from [Arg 4 ] tigerinin-1R-treated mice, providing evidence that the proteins may be targets for the actions of the action peptide in stimulating insulin release in this animal model. These beneficial effects of [Arg 4 ]tigerinin-1R on glucose tolerance and insulin secretion are similar to those observed for magainin-AM2 (Ojo et al., 2015b) , suggesting a similar molecular mechanism of action.
The aim of the patch-clamp experiments was to examine the direct effects of the peptide on the activity of the K ATP and L-type calcium channels in BRIN-BD11 cells under conditions in which the cells are voltage-clamped. Electrophysiological recording of K ATP and L-type Ca 2+ currents in BRIN-BD11 pancreatic β cells indicated that short term application of [Arg 4 ]tigerinin-1R inhibits K ATP channels with no immediate direct effect on the activity of L-Type Ca 2+ channels. This suggests that depolarisation induced by action on K ATP channels and resulting elevation of cytoplasmic Ca 2+ (Ojo et al., 2011) may be sufficient for the peptide to have acute effects on insulin secretion independent of its long-term actions on islet gene expression. It is suggested that the peptide binds to the K ATP channels, hence preventing K + movement through the pore, whereas it does not bind directly to the L-type calcium channels to inhibit or enhance their activity. However, under nonvoltage clamp conditions (i.e. under normal conditions in vivo), blockage of the K ATP channels with resulting depolarization of the cells would be expected to indirectly increase the activity of the L-type Ca channels and so increase Ca 2+ influx through these channels. In addition to β-cell dysfunction, high-fat fed mice exhibited marked insulin resistance. Insulin signalling involves the binding of insulin to the α-subunit of the insulin receptor and the activation of the tyrosine kinase in the β-subunit with the subsequent autophosphorylation (White et al., 1988 ). This in turn leads to the activation of other key molecules such as Irs1, Pik3ca and Pdk1 through which insulin mediates most of its metabolic effects, including the recruitment of the GLUT4 transporter (Wilcox, 2005; Samuel and Shulman, 2012) . Gene expression analysis ( Figure 4J ) indicated that high-fat feeding is associated with significant downregulation of the GLUT4 glucose transporter gene expression in skeletal muscle which is one of the major sites for insulinmediated glucose uptake (Richter and Hargreaves, 2013) . Expression of the insulin receptor (Insr), insulin receptor substrate 1 (Irs1), (phosphatidylinositol-4,5-bisphosphate 3-kinase) Pik3ca and phosphoinositide dependent kinase 1 (Pdk1) is also downregulated in high-fat fed mice, an observation that is consistent with reduced insulin action in obesity-diabetes (Saini, 2010) . In contrast to the effect of tigerinin-1R (Ojo et al., 2015a) , insulin sensitivity was significantly improved in mice treated with [Arg 4 ]tigerinin-1R. Analysis of effects of the analogue on gene expression in skeletal muscle strongly suggests that the peptide improves insulin sensitivity via upregulation of these key genes involved in glucose uptake and insulin action.
The mechanism by which [Arg 4 ]tigerinin-1R alters the expression of a range of genes in the pancreatic islets and skeletal muscle is a matter for speculation. Several strongly cationic host-defense peptides, particularly histone-derived peptides such as buforin IIb (Lee et al., 2008) and hipposin C (Bustillo et al., 2014) have been shown to traverse the plasma membrane of eukaryotic cells without producing permeabilization or disruption, translocate to the nucleus and bind to DNA. It is possible that the effects of strongly cationic [Arg 4 ]tigerinin-1R (charge at pH 7 = +3) on transcription may involve a similar mechanism.
In addition to impaired cellular glucose uptake, unrestrained hepatic glucose output and hyperglucagonaemia make important contributions to hyperglycaemia in diabetes (D'Alessio, 2011). Treatment with [Arg 4 ]tigerinin-1R normalized elevated pancreatic and plasma glucagon concentrations and downregulated expression of the glucagon Gcg gene in the pancreata of high-fat fed mice without affecting α-cell area. These effects are similar to those produced by GLP-1 (De Marinis et al., 2010) . Consequently, it seems likely that the inhibition of glucagon secretion contributes to the improvement of hyperglycaemia and glucose tolerance observed in [Arg 4 ]tigerinin-1R-treated mice. Elevated levels of triglyceride in tissue and blood are obvious consequences of prolonged consumption of a highfat diet (Gao et al., 2015) . In this study, treatment with [Arg 4 ] tigerinin-1R did not affect circulating cholesterol levels but significantly decreased hypertriglyceridaemia and reduced adipose tissue deposition. Both effects can be expected to contribute to the observed improvement of insulin sensitivity (Wald et al., 2012) . Similar to observations reported for other amphibian host defence peptides (Ojo et al., 2015a,b; Srinivasan et al., 2015 Srinivasan et al., , 2016 , 28 day treatment with [Arg 4 ] tigerinin-1R did not affect markers of liver and kidney function indicative of lack of short-term toxicity. The peptide attenuated the elevation of plasma creatinine caused by high-fat feeding (Supplementary Figure 3) .
The potential of tigerinin-1R analogs, indeed all peptide-based therapeutic agents, to treat patients with Type 2 diabetes is limited by their rapid clearance from the circulation. In the case of drugs based upon the structure of GLP-1, this problem has been largely overcome by designing analogs that incorporate of D-amino acids to increase stability to peptidases and/or by addition of a fatty acid moiety that facilitates binding to albumin (Østergaard et al., 2016) . Several such analogs are in clinical practice or undergoing clinical trials but some concerns have been raised regarding possible side-effects and safety (Consoli and Formoso, 2015) . An alternative approach to prolonging the half-life of a peptide in the circulation is pegylation which involves the covalent coupling of a polyethylene glycol group and several pegylated drugs are in routine clinical usage (Ginn et al., 2014) . Future research efforts will employ these strategies to prepare long-acting analogs of tigerinin-1R for testing in vivo.
In conclusion, this study has confirmed that peptides based on the structure of tigerinin-1R are potentially useful agents for the treatment of type 2 diabetes. Administration of [Arg 4 ]tigerinin-1R improved glucose tolerance, enhanced insulin secretion and ameliorated insulin resistance in high-fat fed mice. Antidiabetic actions of the peptide were associated with the upregulation of key genes involved in both insulin secretion and action, a decrease in hyperglucagonaemia, and direct effects on K ATP channels involved in insulin release. The improvement of insulin sensitivity observed with [Arg 4 ]tigerinin-1R, but not with native tigerinin-1R (Ojo et al., 2015a) , indicates that increasing the cationicity of tigerinin-1R enhances its therapeutic utility. These observations together with the lack of toxic effects of [Arg 4 ]tigerinin-1R encourage the development of longacting analogues for the treatment of type 2 diabetes.
Materials and methods
Peptide synthesis and purification [Arg 4 ]tigerinin-1R (RVCRAIPLPICH.NH 2 ) was purchased in crude form GL Biochem Ltd (Shanghai, China) and purified using reversedphase HLPC on a (2.2 cm × 25 cm) Vydac 218TP1022 (C18) column (Grace, Hesperia, CA, USA) equilibrated with acetonitrile/water/triflouroacetic acid (21.0/78.9/0.1 v/v) mobile phase at a flow rate of 6 ml/min. The concentration of acetonitrile in the eluting buffer was raised to 56% (v/v) over 60 min. The molecular mass of the peptide was confirmed using MALDI-TOF mass spectrometry.
Laboratory animals
Male National Institutes of Health (NIH) Swiss mice (Harlan Ltd, UK) were used. Animals were housed in an air-conditioned room (22±2 o C) with regulated light:dark cycle and maintained on a high-fat diet containing 45% fat, 20% protein and 35% carbohydrate (total energy 19.5 kJ g -1 , Dietex International Ltd, Witham, UK) for 120 days to induce obesity-diabetes (Ojo et al., 2015a) . Lean mice maintained on standard rodent diet containing 10% fat, 30% protein and 60% carbohydrates (total energy 12.99 kJ g -1 ) were used as controls. Both groups of animals were allowed food and water ad libitum. All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal experiments.
In vivo studies
High-fat fed mice (n = 8) were administered saline (0.9% (w/v) or [Arg 4 ]tigerinin-1R (75 nmol/kg body weight) every 12 h for 28 days. The peptide dose used in the study was determined following a pilot study that assessed acute effects of different peptide doses (0-150 nmol/ kg body weight) on glucose tolerance. Energy intake, body weight, non-fasting blood glucose and plasma insulin concentrations were measured 3 days prior to and every 72 h during the study. Glycaemic responses following oral or intraperitoneal glucose administration (18 mmol/kg body weight) and insulin sensitivity tests (25 U/kg body weight) were assessed in peptide-treated and control mice after the 28 days treatment period (Moran et al., 2014; Srinivasan et al., 2015) . Terminal analysis included measurement of total body lean and fat mass, bone mineral density and bone mineral content by dual energy X-ray absorptiometry (DEXA) scanning (Piximus Densitometer, GE Medical Systems, Waukesha, WI, USA). Improvement in β-cell function in [Arg 4 ]tigerinin-1R-treated and control mice were evaluated from the insulin secretory responses of islets isolated from these animals to established insulin secretagogues and incretin hormones as previously described (Srinivasan et al., 2015) . Changes in islet morphology were assessed using pancreata excised from mice treated with [Arg 4 ]tigerinin-1R or saline for 28 days as previously described ( Srinivasan et al., 2015) .
Biochemical measurements
Blood samples (approximately 150 μl) were collected from the tail vein of unanaesthetised mice at intervals indicated in the figures for blood glucose measurements and determination of plasma insulin. Blood glucose was measured using a hand-held Ascencia Contour meter (Bayer Healthcare, UK). Plasma and pancreatic insulin were determined by radioimmunoassay (Flatt and Bailey, 1981) while plasma and pancreatic glucagon were determined by ELISA using commercially available kit (Millipore, Billerica, MA, USA). Plasma creatinine, alanine transaminase (ALT), aspartic acid transaminase (AST) and alkaline phosphatase (ALP) were measured using commercially available kits (Randox Laboratories, UK) as indicators of renal and liver function (Ojo et al., 2015b) . Plasma lipid profiles were determined by measuring the concentrations of triglyceride and cholesterol using an automated clinical chemistry analyser (I-lab 650). The assay kit for cholesterol was obtained from Randox Laboratories (Antrim, UK). Estimation of LDL cholesterol was achieved using the Friedewald equation (Moran et al., 2014) .
Gene expression analysis
The primers used in the quantitation of gene expression and the names of the genes investigated are shown in Table 1 . mRNA was extracted from islets isolated from pancreatic tissues as well as from skeletal muscles excised from control and peptide-treated mice using RNeasy mini kit (Qiagen, Manchester, UK) according to the manufacturer's instructions. mRNA samples (1-3 μg) were converted to cDNA using Superscript II reverse transcriptase RNase H kit (Invitrogen, Paisley, UK). Real-time reverse transcription polymerase chain reactions RT-(PCR), with a reaction mixture containing 12.5 μl PCR master mix, 1 μl primers (forward and reverse, Invitrogen, Paisley, UK), 1 μl cDNA and 9.5 μl RNase-free water, were carried out using a Quantifast SYBR green (PCR) kit (Qiagen, Manchester, UK). The amplification program involved initial denaturation at 95°C for 5 min, final denaturation at 95°C for 30 s, annealing at 58°C for 30 s, extension at 72°C for 30 s and a melting curve analysis at a temperature range of 60-90°C. The β-actin gene (ActB) was used as a positive control for each experiment. Data acquisition was achieved using MiniOpticon two-colour RT-PCR detection system (BioRad, Hertfordshire, UK) and results were analyzed using the DDCt method, with mRNA expression normalized to ActB.
Patch clamp analysis
BRIN-BD11 mouse clonal β-cells were seeded on circular 16 mm coverslips in 6-well plates at a density of 40,000 cells/well and allowed to grow overnight at 37°C in 95% O 2 -5% CO 2 in RPMI-1640 media with 10% foetal calf serum and antibiotics as detailed previously ( Srinivasan et al., 2014) . Coverslips were transferred to a glass bottomed recording bath on the stage of an inverted microscope (Nikon Eclipse TE300) and superfused with normal external solution (composition in mm: 140 NaCl, 5 KCl, 2.5 Glucose, 1.3 MgCl 2 , 2 CaCl 2 , 10 HEPES; pH 7.4) at 37°C. Ionic currents were recorded using an Axopatch 200B patch clamp amplifier (Molecular Devices, CA, USA). Data acquisition and analysis were performed using pCLAMP software (Version 10.2). Ionic currents were recorded using the whole-cell mode of the patch clamp technique. Pipettes were pulled with tip resistances of 1-2 MΩ from filamented borosilicate glass capillaries (Harvard Apparatus, Cambridge UK). Amphotericin B (0.39 mm) was included in the pipette solutions to perforate the membrane and reduce current run-down. Signals were sampled at 2 kHz and low-pass filtered at 0.5 kHz. Liquid junction potentials, cell capacitance (6.5-13 pF) and series resistance were routinely compensated and only recordings with stable series resistances < 15 MΩ were included in the study. Current densities were calculated by dividing current amplitudes by the whole-cell capacitance. Solutions containing test substances were applied using a gravity-driven perfusion system with an exchange time of approximately 1 s (Scholfield and Curtis, 2000) .
K ATP currents were elicited by ramp protocols from +20 to -80 mV applied over 1 s from a holding potential of 0 mV using high K + external solution (composition in mm: 130 KCl, 10 TEACl, 2.5 glucose, 1.3 MgCl 2 , 2 CaCl 2 , 10 HEPES; pH 7.4). Penitrem A (100 nm) and nimodipine (1 μm) were added to inhibit BK and L-Type Ca 2+ channels and a K ]tigerinin-1R. It was necessary to perform the experiments in the presence of diazoxide as there was very little K ATP current in the absence of this activator under the experimental conditions used. Control experiments (n = 5) were carried out in which recording were made in the presence of diazoxide (200 μm) but without addition of the test peptide. Current amplitudes at 10 mV intervals were measured offline to enable statistical analyses.
L-Type Ca 2+ currents were elicited with depolarising voltage steps from -60 mV to membrane potentials between -50 and +40 mV in 10 mV increments (step duration 1 s, applied every 10 s) using a Ba 2+ external solution (composion in mm: 140 NaCl, 5 KCl, 2.5 Glucose, 1.3 MgCl 2 , 10 BaCl 2 , 10 HEPES; pH 7.4). Penitrem A (100 nm), tetrodotoxin (1 μm) and glibenclamide (100 μm) were added to inhibit BK, Na + and K ATP channels and a Cs + based internal solution was used (composition in mm: 120 CsCL, 1 MgCl 2 , 4 Na 2 ATP, 10 BAPTA, 10 HEPES, pH 7.2 with CsOH). L-Type Ca 2+ current amplitude was measured as the initial peak current with respect to that at the end of each test step.
Statistical analysis
Results are expressed as mean±S.E.M. Values were compared using one-way ANOVA followed by Student-Newman-Keuls post hoc test. Area under the curve (AUC) analysis was performed using the trapezoidal rule with baseline correction. Membrane current-voltage relations were compared using 2-way repeated measures ANOVA with Bonferroni post hoc test. p < 0.05 was considered statistically significant.
